Author

N. Pishesha

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

H. Ploegh· 3 shared A. C. Williams· 1 shared A. Eaton· 1 shared A. J. B. Kreutzberger· 1 shared A. J. Quartararo· 1 shared A. Loas· 1 shared A. R. Loftis· 1 shared A. Saminathan· 1 shared

Activity by Year

2020-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

H. Ploegh

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Nanobody-targeted conditional antimicrobial therapeutics

C. Ngambenjawong, H. Ko, N. Pishesha, H. L. Ploegh, S. N. Bhatia

This study designs nanobody-targeted conditional antimicrobial therapeutics to deliver therapeutic cargos to bacterial infection sites by enhancing protease activation through proximity-enabled reactivity.

ACS Nano · Mar 5, 2025Peer-reviewedBioengineering

Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism

S. Luo, J. Zhang, A. J. B. Kreutzberger, A. Eaton, R. J. Edwards, C. Jing, H.-Q. Dai, G. D. Sempowski, K. Cronin, R. Parks, A. Y. Ye, K. Mansouri, M. Barr, N. Pishesha, A. C. Williams, , F. W. Alt

The paper describes a humanized antibody, SP1-77, that neutralizes all SARS-CoV-2 variants by blocking membrane fusion instead of ACE2 receptor binding.

bioRxiv · Jun 26, 2022 · PreprintImmunology

Engineered Red Blood Cells Carrying PCSK9 Inhibitors Persistently Lower LDL and Prevent Obesity

R. Deshycka, V. Sudaryo, N.-J. Huang, Y. Xie, L. Y. Smeding, M. K. Choi, H. Ploegh, H. Lodish, N. Pishesha

This study develops engineered red blood cells expressing a PCSK9 inhibitor to lower LDL and prevent obesity in mice.

bioRxiv · Nov 2, 2020Bioengineering

Erythrocyte-targeted immunomodulatory antigens enabled by in vivo selection of D-peptides

A. R. Loftis, G. Zhang, C. Backlund, A. J. Quartararo, N. Pishesha, C. K. Schissel, D. Garafola, A. Loas, R. J. Collier, H. Ploegh, D. J. Irvine, B. L. Pentelute

The paper identifies a D-peptide that targets murine erythrocytes and reduces anti-drug antibody responses when conjugated to therapeutic proteins.

bioRxiv · Jul 15, 2020 · PreprintBioengineering